IO Biotech, Inc.
IOBT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $1 | $0 |
| Gross Profit | -$1 | -$1 | -$1 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $71 | $68 | $47 | $30 |
| G&A Expenses | $0 | $0 | $0 | $11 |
| SG&A Expenses | $23 | $23 | $24 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $94 | $91 | $71 | $41 |
| Operating Income | -$95 | -$91 | -$71 | -$41 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $6 | $1 | -$27 |
| Pre-Tax Income | -$94 | -$85 | -$70 | -$68 |
| Tax Expense | $1 | $1 | $1 | $0 |
| Net Income | -$95 | -$86 | -$71 | -$68 |
| % Margin | – | – | – | – |
| EPS | -1.45 | -1.98 | -2.48 | -2.36 |
| % Growth | 26.8% | 20.2% | -5.1% | – |
| EPS Diluted | -1.45 | -1.98 | -2.48 | -2.36 |
| Weighted Avg Shares Out | 66 | 44 | 29 | 29 |
| Weighted Avg Shares Out Dil | 66 | 44 | 29 | 29 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $6 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$93 | -$84 | -$69 | -$67 |
| % Margin | – | – | – | – |